UNSPSC 51201901: Glatiramer acetate

This classification denotes a biological response modifier with the molecular formula (C9H9NO2)n.(C6H12N2O)n.(C5H7NO3)n.(C3H5NO)n.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5M691HL4BO, chemically known as l-glutamic acid polymer with l-alanine, l-lysine and l-tyrosine, acetate (salt) but generally known as glatiramer acetate, which bears US NIH Compound Identifier 3081884. European Medicines Agency schedules Glatiramer acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13971MIG.

UNSPSC 51201901 Glatiramer acetate is a Commodity code that nominally describes a disease-modifying therapy for multiple sclerosis, but the recent state and local opportunities posted under this code show little to no alignment with pharmaceutical procurement. The three most recent opportunities span a District Attorney's office dog acquisition in Oregon, athletic training services for fire and police departments in Arizona, and medical aid supplies for a fire rescue department in Florida — none of which involve glatiramer acetate or pharmaceutical product procurement. The code appears to be misapplied or mistagged in the source opportunities, and does not currently reflect meaningful pharmaceutical or health-service purchasing activity under its nominal scope.

No recent state and local opportunities documented in the source represent actual glatiramer acetate procurement or services functionally related to the code's pharmaceutical classification. Vendors evaluating this code for business development should verify whether state and local procurement offices are actively using 51201901 for its intended pharmaceutical scope or whether the tagging represents data-quality issues in the underlying opportunity feeds. The mismatch between the code's name and the posted opportunities suggests limited current utility for pursuing contracts under this Commodity classification.